Journal article
Galectin-3 levels are elevated following nintedanib treatment
Abstract
BACKGROUND AND AIMS: Idiopathic pulmonary fibrosis (IPF) is a common and severe form of pulmonary fibrosis. Nintedanib, a triple angiokinase inhibitor, is approved for treating IPF. Galectin 3 (Gal-3) activates a variety of profibrotic processes. Currently, the Gal-3 inhibitor TD139 is being tested in phase II clinical trials. Since this treatment is given 'on top' of nintedanib, it is important to estimate its effect on Gal-3 levels. …
Authors
Shochet GE; Pomerantz A; Shitrit D; Bardenstein-Wald B; Ask K; Surber M; Rabinowicz N; Levy Y; Benchetrit S; Edelstein E
Journal
Therapeutic Advances in Chronic Disease, Vol. 11, ,
Publisher
SAGE Publications
Publication Date
January 2020
DOI
10.1177/2040622320968412
ISSN
2040-6223